AssetMark Inc’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $55.6M | Buy |
60,441
+1,558
| +3% | +$1.58M | 0.11% | 158 |
|
|
2025
Q4 | $63.3M | Buy |
58,883
+3,523
| +6% | +$3.37M | 0.13% | 133 |
|
|
2025
Q3 | $42.2M | Buy |
55,360
+3,142
| +6% | +$2.34M | 0.09% | 181 |
|
|
2025
Q2 | $40.7M | Buy |
52,218
+7,240
| +16% | +$5.63M | 0.1% | 177 |
|
|
2025
Q1 | $37.1M | Buy |
44,978
+2,383
| +6% | +$1.98M | 0.1% | 169 |
|
|
2024
Q4 | $32.9M | Sell |
42,595
-7,118
| -14% | -$5.89M | 0.09% | 181 |
|
|
2024
Q3 | $44M | Buy |
49,713
+3,397
| +7% | +$3.05M | 0.13% | 151 |
|
|
2024
Q2 | $41.9M | Buy |
46,316
+3,355
| +8% | +$2.68M | 0.13% | 147 |
|
|
2024
Q1 | $33.4M | Buy |
42,961
+2,563
| +6% | +$1.82M | 0.11% | 166 |
|
|
2023
Q4 | $23.5M | Buy |
40,398
+1,092
| +3% | +$637K | 0.09% | 186 |
|
|
2023
Q3 | $21.1M | Buy |
39,306
+88
| +0.2% | +$45.3K | 0.08% | 181 |
|
|
2023
Q2 | $18.4M | Sell |
39,218
-2,857
| -7% | -$1.2M | 0.07% | 194 |
|
|
2023
Q1 | $14.4M | Buy |
42,075
+3,445
| +9% | +$1.16M | 0.06% | 202 |
|
|
2022
Q4 | $14.1M | Sell |
38,630
-150,630
| -80% | -$53.4M | 0.06% | 202 |
|
|
2022
Q3 | $61.2M | Buy |
189,260
+16,477
| +10% | +$5.22M | 0.29% | 80 |
|
|
2022
Q2 | $56M | Buy |
172,783
+6,911
| +4% | +$2.07M | 0.25% | 89 |
|
|
2022
Q1 | $47.5M | Buy |
165,872
+6,857
| +4% | +$1.76M | 0.2% | 114 |
|
|
2021
Q4 | $43.9M | Buy |
159,015
+6,235
| +4% | +$1.58M | 0.18% | 129 |
|
|
2021
Q3 | $35.3M | Buy |
152,780
+5,245
| +4% | +$1.29M | 0.16% | 144 |
|
|
2021
Q2 | $33.9M | Sell |
147,535
-183,289
| -55% | -$36.8M | 0.16% | 147 |
|
|
2021
Q1 | $61.8M | Sell |
330,824
-357,780
| -52% | -$70M | 0.32% | 88 |
|
|
2020
Q4 | $116M | Buy |
688,604
+67,276
| +11% | +$10M | 0.65% | 42 |
|
|
2020
Q3 | $92M | Buy |
621,328
+97,100
| +19% | +$15M | 0.59% | 46 |
|
|
2020
Q2 | $81.9M | Buy |
524,228
+53,497
| +11% | +$8.21M | 0.59% | 43 |
|
|
2020
Q1 | $65.3M | Sell |
470,731
-46,135
| -9% | -$6.34M | 0.55% | 51 |
|
|
2019
Q4 | $67.9M | Buy |
516,866
+36,566
| +8% | +$4.24M | 0.52% | 51 |
|
|
2019
Q3 | $53.7M | Buy |
480,300
+69,966
| +17% | +$7.79M | 0.45% | 58 |
|
|
2019
Q2 | $45.5M | Buy |
410,334
+50,087
| +14% | +$5.9M | 0.37% | 68 |
|
|
2019
Q1 | $46.7M | Buy |
360,247
+16,632
| +5% | +$2.02M | 0.42% | 63 |
|
|
2018
Q4 | $39.8M | Buy |
343,615
+342,113
| +22,777% | +$38.2M | 0.38% | 69 |
|
|
2018
Q3 | $161K | Sell |
1,502
-296
| -16% | -$29.6K | ﹤0.01% | 490 |
|
|
2018
Q2 | $153K | Sell |
1,798
-55
| -3% | -$4.52K | ﹤0.01% | 493 |
|
|
2018
Q1 | $143K | Sell |
1,853
-6,231
| -77% | -$502K | ﹤0.01% | 499 |
|
|
2017
Q4 | $683K | Sell |
8,084
-3,090
| -28% | -$263K | 0.01% | 327 |
|
|
2017
Q3 | $956K | Sell |
11,174
-4,701
| -30% | -$386K | 0.01% | 301 |
|
|
2017
Q2 | $1.31M | Buy |
15,875
+2,962
| +23% | +$242K | 0.02% | 269 |
|
|
2017
Q1 | $1.09M | Buy |
12,913
+8,953
| +226% | +$717K | 0.01% | 279 |
|
|
2016
Q4 | $291K | Sell |
3,960
-18,566
| -82% | -$1.38M | ﹤0.01% | 372 |
|
|
2016
Q3 | $1.81M | Sell |
22,526
-2,598
| -10% | -$208K | 0.03% | 223 |
|
|
2016
Q2 | $1.98M | Sell |
25,124
-3,294
| -12% | -$248K | 0.03% | 220 |
|
|
2016
Q1 | $2.05M | Buy |
28,418
+23,528
| +481% | +$1.78M | 0.04% | 218 |
|
|
2015
Q4 | $412K | Buy |
4,890
+4,658
| +2,008% | +$387K | 0.01% | 367 |
|
|
2015
Q3 | $19K | Buy |
232
+126
| +119% | +$10.6K | ﹤0.01% | 437 |
|
|
2015
Q2 | $9K | Buy |
+106
| New | +$8.08K | ﹤0.01% | 532 |
|
|
2015
Q1 | – | Sell |
-103
| Closed | -$7K | – | 490 |
|
|
2014
Q4 | $7K | Buy |
+103
| New | +$6.95K | ﹤0.01% | 450 |
|
Other funds holding LLY
VCM
VPM
AssetMark Inc's LLY Position: Q1 2026 in Review
AssetMark Inc increased its Eli Lilly (LLY) stake by 2.6% in Q1 2026, buying an estimated $1.58M and bringing the position to 60,441 shares worth $55.6M. The position accounts for 0.11% of the portfolio, ranked #158.
AssetMark Inc first reported a position in LLY in Q4 2014 and has held it in 45 quarters since. The position peaked at $116M in Q4 2020. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- AssetMark Inc held 60,441 shares of Eli Lilly worth $55.6M as of Q1 2026.
- AssetMark Inc bought 1,558 Eli Lilly shares in Q1 2026, an estimated $1.58M.
- Eli Lilly made up 0.11% of AssetMark Inc's portfolio in Q1 2026, its #158 holding.
- AssetMark Inc first reported a position in Eli Lilly in Q4 2014 and has held it in 45 quarters since.
- AssetMark Inc's Eli Lilly position peaked at $116M in Q4 2020.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.